Tenet Healthcare Corporation (THC)
| Market Cap | 23.11B +27.4% |
| Revenue (ttm) | 22.15B +6.2% |
| Net Income | 2.90B +114.1% |
| EPS | 34.11 +134.1% |
| Shares Out | 79.59M |
| PE Ratio | 8.51 |
| Forward PE | 14.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 269,332 |
| Open | 297.00 |
| Previous Close | 292.25 |
| Day's Range | 290.40 - 301.44 |
| 52-Week Range | 157.58 - 299.76 |
| Beta | 1.20 |
| Analysts | Buy |
| Price Target | 304.14 (+4.73%) |
| Earnings Date | Oct 29, 2026 |
About THC
Tenet Healthcare Corporation operates as a diversified healthcare services company in the United States. The company operates through two segments: Hospital Operations and Services, and Ambulatory Care. Its general hospitals offer acute care services, operating and recovery rooms, radiology and respiratory therapy services, clinical laboratories, and pharmacies. The company also provides intensive and critical care, and/or coronary care units; cardiovascular, digestive disease, neurosciences, musculoskeletal, and obstetrics services; outpatient... [Read more]
Financial Performance
In 2025, Tenet Healthcare's revenue was $21.31 billion, an increase of 3.07% compared to the previous year's $20.68 billion. Earnings were $1.41 billion, a decrease of -56.03%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for THC stock is "Buy." The 12-month stock price target is $304.14, which is an increase of 4.73% from the latest price.
News
Healthcare Stocks Bounce on Midterm Results. A Bull Market Case Is Developing.
The stocks of big operators in state Medicaid programs, Affordable Care Act markets and hospital groups all jumped.
Tenet Healthcare price target raised to $297 from $271 at Barclays
Barclays raised the firm’s price target on Tenet Healthcare (THC) to $297 from $271 and keeps an Overweight rating on the shares. The company “demonstrated positively differentiated hospital performan...
Tenet Healthcare price target raised to $300 from $270 at KeyBanc
KeyBanc analyst Matthew Gillmor raised the firm’s price target on Tenet Healthcare (THC) to $300 from $270 and keeps an Overweight rating on the shares. The firm is updating its…
Tenet Healthcare price target raised to $342 from $309 at Leerink
Leerink raised the firm’s price target on Tenet Healthcare (THC) to $342 from $309 and keeps an Outperform rating on the shares. The firm notes Q3 results underscore the strong…
Tenet Healthcare price target raised to $302 from $263 at TD Cowen
TD Cowen raised the firm’s price target on Tenet Healthcare (THC) to $302 from $263 and keeps a Buy rating on the shares. The firm updated its model following Q3…
Tenet Healthcare price target raised to $305 from $290 at Mizuho
Mizuho raised the firm’s price target on Tenet Healthcare (THC) to $305 from $290 and keeps an Outperform rating on the shares. The firm views the company’s Q3 report as…
Tenet Healthcare price target raised to $304 from $283 at RBC Capital
RBC Capital raised the firm’s price target on Tenet Healthcare (THC) to $304 from $283 and keeps an Outperform rating on the shares. The firm is updating its model following…
Tenet Healthcare price target raised to $321 from $281 at Wells Fargo
Wells Fargo analyst Stephen Baxter raised the firm’s price target on Tenet Healthcare (THC) to $321 from $281 and keeps an Overweight rating on the shares. The firm says that…
Tenet Healthcare price target raised to $297 from $274 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $297 from $274 and keeps an Overweight rating on the shares.
Tenet Healthcare price target raised to $300 from $285 at Raymond James
Raymond James raised the firm’s price target on Tenet Healthcare (THC) to $300 from $285 and keeps an Outperform rating on the shares. Tenet’s Q3 results were fundamentally in line,…
Tenet Healthcare price target lowered to $306 from $307 at Guggenheim
Guggenheim lowered the firm’s price target on Tenet Healthcare (THC) to $306 from $307 and keeps a Buy rating on the shares as the firm updated estimates following earnings. Published…
Tenet Healthcare price target raised to $285 from $280 at Baird
Baird raised the firm’s price target on Tenet Healthcare (THC) to $285 from $280 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results…
Tenet Healthcare sees overall adjusted EBITDA growth in 2027
Comments taken from Q3 earnings conference call.
Tenet Healthcare Earnings Call Transcript: Q3 2026
Q3 revenue was $5.6B and adjusted EBITDA was $1.355B; FY26 EBITDA guidance rose to $5.05B–$5.2B. Exchange pressure persisted, while USPI growth and disciplined costs supported results and 2027 growth expectations excluding one-time Conifer transitions.
Tenet Healthcare Earnings release: Q3 2026
Tenet Healthcare released its Q3 2026 earnings on October 29, 2026, summarizing the period's financial results.
Tenet Healthcare Slides: Q3 2026
Tenet Healthcare has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 29, 2026.
Tenet Healthcare Quarterly report: Q3 2026
Tenet Healthcare has published its Q3 2026 quarterly earnings report on October 29, 2026.
Tenet Healthcare sees FY26 adjusted EPS $22.05-$23.01, consensus $21.23
Now sees FY26 revenue $22.05B-$22.45B, consensus $22.42B. FY 2026 Adjusted EBITDA Outlook is now expected to be in the range of $5.05B to $5.2B, a $195M increase at the midpoint…
Tenet Healthcare reports Q3 adjusted EPS $6.64, consensus $4.68
Reports Q3 net revenue $5.63B, consensus $5.51B. “Our outperformance in the third quarter of 2026 was driven by sustained strength in same-store revenue growth and effective expense management,” said ...
Tenet Reports Strong Third Quarter 2026 Results; Raises 2026 Financial Outlook
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (Tenet) (NYSE: THC) today announced its results for the quarter ended September 30, 2026. "Our outperformance in the third quarter of 2026 was dri...
Tenet Healthcare price target raised to $307 from $283 at Guggenheim
Guggenheim raised the firm’s price target on Tenet Healthcare (THC) to $307 from $283 and keeps a Buy rating on the shares. The firm anticipates Tenet will “stick to its…
Tenet to Report Its Third Quarter 2026 Results on October 29
DALLAS--(BUSINESS WIRE)--Tenet Healthcare Corporation (NYSE: THC) will release its third quarter 2026 results before the market opens on Thursday, October 29, 2026, to be followed by a conference call...
BMO starts Tenet at Market Perform, says execution reflected in valuation
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target Tenet’s expanding Ambulatory business increasingly leverages it to an end-market with more f...
Tenet Healthcare initiated with a Market Perform at BMO Capital
BMO Capital initiated coverage of Tenet Healthcare (THC) with a Market Perform rating and $265 price target